Core Insights - Artiva Biotherapeutics, Inc. has appointed Elaine Sorg to its Board of Directors, bringing over 35 years of experience in the biopharmaceutical industry, particularly in immunology therapies [1][2] - The company is preparing to share clinical activity data from its AlloNK regimen for rheumatoid arthritis and engage with the FDA for a registrational trial, indicating a significant phase in its development [2] - AlloNK is positioned as a potentially transformative treatment for autoimmune diseases, with a focus on B-cell depletion and improved efficacy compared to existing therapies [2][4] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers, with its lead program being AlloNK, a non-genetically modified NK cell therapy [4][5] - The company was founded in 2019 as a spin-out from GC Cell, acquiring exclusive worldwide rights to NK cell manufacturing technology [4] Leadership Experience - Elaine Sorg has held senior executive roles at major pharmaceutical companies, including AbbVie and Eli Lilly, where she was instrumental in the commercialization of key immunology products [2][3] - Her experience includes leading U.S. commercialization efforts for a broad portfolio of medicines and overseeing major autoimmune disease brands [2][3]

Core Insights - AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals' investigational candidate, bretisilocin, which is in Phase 2 development for treating major depressive disorder (MDD) [1][3]. Group 1: Acquisition Details - The acquisition enhances AbbVie's psychiatry pipeline with a next-generation psychedelic compound aimed at addressing challenges associated with classic psychedelic treatments [1][2]. - Bretisilocin is a short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser, currently in Phase 2 clinical trials for moderate-to-severe MDD [2]. Group 2: Clinical Development and Commitment - Recent clinical results indicate bretisilocin's potential effectiveness in treating patients with MDD, reinforcing AbbVie's commitment to innovative treatment options for serious mental health conditions [3]. - AbbVie aims to accelerate the development of bretisilocin following the acquisition, highlighting its focus on science-driven solutions in neuroscience [3]. Group 3: Company Overview - AbbVie's mission is to discover and deliver innovative medicines that address serious health issues across various therapeutic areas, including neuroscience [4].